Abstract Number: 412 • 2017 ACR/ARHP Annual Meeting
Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity
Background/Purpose: Forefoot deformities are commonly seen in patients with RA. It has been reported that nearly 90% of the patients have foot problems.1,2 Patients with…Abstract Number: 413 • 2017 ACR/ARHP Annual Meeting
Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibody positivity has been suggested as a strong predictor of joint erosion as well as a potential biomarker for guiding…Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 415 • 2017 ACR/ARHP Annual Meeting
Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1/JAK2.1 In the European Union, bari is approved for the treatment of moderate…Abstract Number: 416 • 2017 ACR/ARHP Annual Meeting
The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX
Background/Purpose: Maturation of autoantibody responses has been suggested to be a proxy for disease maturation. Autoantibody responses against post-translationally modified antigens are present in autoimmune…Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…Abstract Number: 418 • 2017 ACR/ARHP Annual Meeting
Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline
Background/Purpose: Baricitinib (BARI), an oral inhibitor of Janus kinase (JAK)1 and JAK2, is being developed for the treatment of RA. RA-BEGIN (NCT01711359) was a phase…Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting
Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience
Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…Abstract Number: 420 • 2017 ACR/ARHP Annual Meeting
Machine Learning in Rheumatology: Development and Validation of a Predictive Model for Rheumatoid Arthritis Mortality Using Random Survival Forests
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality. Traditional survival techniques used to identify mortality risk factors, such as the Cox proportional hazards model…Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…Abstract Number: 425 • 2017 ACR/ARHP Annual Meeting
Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry
Background/Purpose: To report the prevalence and efficacy of biologic DMARD (bDMARD) monotherapy in real life treatment of rheumatoid arthritis (RA). Methods: RA patients registered in…Abstract Number: 426 • 2017 ACR/ARHP Annual Meeting
Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
Background/Purpose: To study the correlation between levels of the anti-TNF biologics and clinical efficacy in patients with inflammatory arthritis Methods: Adult patients who fulfilled the…
ACR Meeting Abstracts